Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach

Methods in Molecular Biology

Volumn 987, Issue , 2013, Pages 11-23

  Zientek, Michael ^a   Youdim, Kuresh ^b  

^a PFIZER INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cassette of substrates; Cocktail of substrates; CYP1A2; CYP2C19; CYP2C9; CYP2D6; CYP3A; Cytochrome P450; Drug drug interaction; LC MS MS; Liquid chromatography tandem mass spectrometry

Indexed keywords

4 HYDROXYDICLOFENAC; 4' HYDROXYMEPHENYTOIN; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; DICLOFENAC; DRUG METABOLITE; MEPHENYTOIN; MIDAZOLAM; TACRINE; TRIAZOLAM; UNCLASSIFIED DRUG; VELNACRINE; ENZYME INHIBITOR; ISOENZYME;

ARTICLE; COCKTAIL PROBE APPROACH; CONTROLLED STUDY; DRUG DETERMINATION; DRUG INTERACTION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; DRUG ANTAGONISM; GENETIC PROCEDURES; IC 50; METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MICROSOMES, LIVER; MOLECULAR PROBE TECHNIQUES;

EID: 84883009634     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-321-3_2     Document Type: Article

References (41)

1. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, Grahame-Smith DG (1996) Adverse drug reactions in a hospital general medical unit meriting noti fication to the Committee on Safety of Medicines. Br J Clin Pharmacol 42:423-9
2. Issa AM, Phillips KA, Van Bebber S, Nidmarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW (2007) Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf 2:177-185
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metabol Dispos 31:815-32
4. Huang S, Stifano T (2006) C.f.D.E.a.R. (CDER), C.f.B.E.a.R. (CBER) (ed) Draft guidance for industry: drug interaction studies -study design, data analysis, and implications for dosing and labeling. U.S. Department of Health and Human Services Food and Drug Administration.
5. Tucker G, Houston B, Huang S (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential -toward a consensus. Pharmaceut Res V18:1071-1080
6. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-23
7. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-9
8. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug-drug interactions for UDPglucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-8
9. Bu HZ, Knuth K, Magis L, Teitelbaum P (2000) High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Commun Mass Spectrom 14: 1943-8
10. Bu HZ, Knuth K, Magis L, Teitelbaum P (2001) High-throughput cytochrome P450 (CYP) inhibition screening via cassette probedosing strategy: III. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2C19 inhibition evaluation. J Pharm Biomed Anal 25:437-42
11. Bu HZ, Knuth K, Magis L, Teitelbaum P (2001) High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probedosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment. Eur J Pharm Sci 12:447-52
12. Bu HZ, Magis L, Knuth K, Teitelbaum P (2000) High-throughput cytochrome P450 (CYP) inhibition screening via cassette probedosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites. Rapid Commun Mass Spectrom 14:1619-24
13. Bu HZ, Magis L, Knuth K, Teitelbaum P (2001) High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probedosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 15:741-8
14. Bu HZ, Magis L, Knuth K, Teitelbaum P (2001) High-throughput cytochrome P450 (CYP) inhibition screening via cassette probedosing strategy. II. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2D6 inhibition assessment. J Chromatogr B Biomed Sci Appl 753:321-6
15. Gao F, Johnson DL, Ekins S, Janiszewski J, Kelly KG, Meyer RD, West M (2002) Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen 7:373-82
16. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-92
17. Smith D, Sadagopan N, Zientek M, Reddy A, Cohen L (2007) Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J Chromatogr B Analyt Technol Biomed Life Sci 850:455-63
18. Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-60
19. Youdim KA, Lyons R, Payne L, Jones BC, Saunders K (2008) An automated, highthroughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. J Pharm Biomed Anal 48:92-9
20. Zientek M, Miller H, Smith D, Dunklee M, Heinle L, Thurston A, Lee C, Hyland R, Fahmi O, Burdette D (2008) Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 58:206-214
21. Cawley GF, Batie CJ, Backes WL (1995) Substrate-dependent competition of different P450 isozymes for limiting NADPH-cytochrome P450 reductase. Biochemistry 34:1244-7
22. West SB, Lu AY (1972) Reconstituted liver microsomal enzyme system that hydroxylates drugs, other foreign compounds and endogenous substrates. V. Competition between cytochromes P-450 and P-448 for reductase in 3,4-benzpyrene hydroxylation. Arch Biochem Biophys 153:298-303
23. Weaver R, Graham KS, Beattie IG, Riley RJ (2003) Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31: 955-66
24. Hurley JH, Dean AM, Koshland DE Jr, Stroud RM (1991) Catalytic mechanism of NADP(+)-dependent isocitrate dehydrogenase: implications from the structures of magnesium-isocitrate and NADP+ complexes. Biochemistry 30: 8671-8
25. Busby WF Jr, Ackermann JM, Crespi CL (1999) Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 27:246-9
26. Easterbrook J, Lu C, Sakai Y, Li AP (2001) Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141-4
27. Chauret N, Gauthier A, Nicoll-Grif fith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26:1-4
28. Leemann T, Transon C, Dayer P (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4 ¢ -hydroxylation in human liver. Life Sci 52:29-34
29. Wrighton SA, Stevens JC, Becker GW, VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4 ¢ -hydroxylation. Arch Biochem Biophys 306:240-5
30. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the MAJOR (S)-mephenytoin 4 ¢ -hydroxylase in humans. Biochemistry 33:1743-1752
31. Rodrigues AD (1996) Measurement of human liver microsomal cytochrome P450 2D6 activity using (O-methyl-14C)dextromethorphan as substrate. Methods Enzymol 272:186-95
32. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96
33. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-9
34. Obach RS, Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-7
35. Becquemont L, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P, Beaune P (1998) Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 8:101-8
36. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-108
37. Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR (2005) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-8
38. Margolis JM, Obach RS (2003) Impact of nonspeci fic binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606-11
39. Jenkins KM, Angeles R, Quintos MT, Xu R, Kassel DB, Rourick RA (2004) Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition pro filing of combinatorial libraries. J Pharm Biomed Anal 34:989-1004
40. Hewavitharana AK (2011) Matrix matching in liquid chromatography-mass spectrometry with stable isotope labelled internal standards -is it necessary? J Chromatogr A 1218:359-61
41. Youdim KA, Saunders KC (2010) A review of LC-MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s. J Chromatogr B Analyt Technol Biomed Life Sci 878:1326-36